New York State Common Retirement Fund Trims Position in Smith & Nephew SNATS, Inc. $SNN

New York State Common Retirement Fund lowered its position in shares of Smith & Nephew SNATS, Inc. (NYSE:SNN) by 37.8% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 147,985 shares of the medical equipment provider’s stock after selling 89,840 shares during the quarter. New York State Common Retirement Fund’s holdings in Smith & Nephew SNATS were worth $5,370,000 as of its most recent filing with the SEC.

Several other institutional investors also recently bought and sold shares of SNN. AlphaCore Capital LLC acquired a new stake in shares of Smith & Nephew SNATS during the second quarter worth $44,000. Root Financial Partners LLC purchased a new position in Smith & Nephew SNATS during the third quarter worth about $102,000. Bessemer Group Inc. boosted its stake in Smith & Nephew SNATS by 111.9% in the 2nd quarter. Bessemer Group Inc. now owns 3,709 shares of the medical equipment provider’s stock worth $114,000 after buying an additional 1,959 shares during the last quarter. MAI Capital Management grew its holdings in Smith & Nephew SNATS by 24.0% in the 2nd quarter. MAI Capital Management now owns 4,371 shares of the medical equipment provider’s stock valued at $134,000 after buying an additional 846 shares during the period. Finally, GAMMA Investing LLC grew its holdings in Smith & Nephew SNATS by 11.7% in the 3rd quarter. GAMMA Investing LLC now owns 3,837 shares of the medical equipment provider’s stock valued at $139,000 after buying an additional 401 shares during the period. 25.64% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the stock. Canaccord Genuity Group cut their price objective on shares of Smith & Nephew SNATS from $36.00 to $34.00 and set a “hold” rating on the stock in a report on Tuesday, November 11th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Smith & Nephew SNATS in a research note on Wednesday, January 21st. Sanford C. Bernstein set a $37.50 price objective on shares of Smith & Nephew SNATS and gave the company a “market perform” rating in a research note on Tuesday, October 14th. Wall Street Zen upgraded Smith & Nephew SNATS from a “buy” rating to a “strong-buy” rating in a report on Saturday, January 10th. Finally, Kepler Capital Markets raised Smith & Nephew SNATS to a “strong-buy” rating in a research report on Monday, November 17th. One research analyst has rated the stock with a Strong Buy rating and seven have issued a Hold rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $35.75.

Smith & Nephew SNATS Price Performance

Shares of Smith & Nephew SNATS stock opened at $35.12 on Friday. Smith & Nephew SNATS, Inc. has a twelve month low of $23.91 and a twelve month high of $38.79. The company has a quick ratio of 1.40, a current ratio of 3.00 and a debt-to-equity ratio of 0.60. The company has a fifty day moving average price of $33.19 and a 200 day moving average price of $34.60.

Smith & Nephew SNATS Company Profile

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.